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1. Introduction 
The regulation of appetite is regulated by complex mechanism involving brain-gut axis and 
hormonal and non-hormonal factors acting through the activity of satiety and hunger centers 
located in the hypothalamus [Wren & Bloom, 2007]. Among hormones controlling appetite are 
gastrointestinal hormones such as cholecystokinin, PYY, pancreatic polypeptide, glucagon-like 
peptide 1, oxyntomedulin, the endocrine pancreatic hormones including insulin and glucagon 
and endocannabinoids [Wren &Bloom, 2007]. Recent discoveries of ghrelin and orexin-A gave 
a new insight into the understanding of mechanism of appetite control, satiety and obesity. 
Ghrelin is a novel 28-amino acid peptide that has recently been discovered in rat and human 
gastrointestinal tract, particularly in gastric mucosa, as an endogenous ligand for growth 
hormone (GH) secretagogue receptor (GHS-R) [Kojima et al., 1999]. Ghrelin stimulates food 
intake and body weight gain exerting a modulating effect on energy expenditure acting 
through afferent nerves and directly on hypothalamic feeding centers [Kojima et al., 1999; 
Tomasetto et al., 2000]. This peptide was also shown to enhance the gastric motility and gastric 
secretion [Tschop et al., 2000; Date et al., 2001]. Ghrelin is considered as an orexigenic peptide 
produced by the stomach, acting as a meal initiator [Masuda et al., 2000; Ariyasu et al., 2001]. 
Little is known about other factors that might affect ghrelin secretion in the stomach and its 
influence on gastrointestinal integrity has not been fully elucidated. A recent study in humans 
revealed that stomach is a major source of circulating ghrelin and that gastrectomy produced 
dramatic fall in the plasma ghrelin levels, whereas fasting and anorexia nervosa was 
accompanied by elevated plasma ghrelin levels [Ariyasu et al., 2001].  
The orexins also called hypocretins, are neuropeptides novel originally discovered in a small 
group of neurons in the hypothalamic area (LHA) [Sakurai et al., 1998; de Lecea et al., 1998]. 
identified two peptides that were endogenous ligands to orphan receptor HFGAN72 
[Sakurai et al., 1998]. They found that these peptides after i.c.v. injection stimulated food 
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intake and their expression was upregulated upon fasting. Therefore, the group of these 
peptides has been named “orexins” after the Greek word “orexis” meaning appetite 
[Komaki et al., 2001]. The orexin group of peptides was originally identified as regulators of 
food intake and of sleep behavior and act at one or the other of 2 G protein-coupled 
receptors, the orexin-1 (OX-R1) and orexin-2 (OX-R2) receptors [Sakurai et al., 1998; Mondal 
et al., 1999]. OX-A is a 33-residue peptide possessing the identical sequence in humans and 
rodents, whereas human and rat OX-B differ by two residues. OX-A and OX-B activate two 
G protein-coupled receptors known as OX-1 and OX-2, the OX-1 receptor having a greater 
affinity for OX-A over OX-B, whereas the OX-2 receptor has similar affinity for both ligands 
[Sakurai, 2003]. Besides the presence in the brain, orexin-like immunoreactivity was found 
in the ENS of different species including guinea pig, rat, mouse and humans [Kirchgessner 
& Liu, 1999]. Interestingly, the prepro-orexin, orexin A and orexin receptor mRNA 
expression were demonstrated in the myenteric plexus and afferent nerves co-localizing 
with VIP-ergic nerves and in the gastrin-producing cells of the rat stomach [Kirchgessner & 
Liu, 1999]. Orexin-A has been linked with the peripheral energy balance and central nervous 
system mechanisms that coordinate sleep-wakefulness and motivated behaviors such as 
food seeking, especially in physiological state of fasting stress [Mondal et al., 1999; Sakurai, 
2003]. Recent studies in humans revealed that the plasma orexin-A concentrations are 
increased during fasting in humans [Komaki et al., 2001].   
The question remains as to whether these newly discovered peptides could play a role in the 
mechanism of gastric integrity and gastric mucosal defense has not been fully explored. 
Both, ghrelin and orexin-A were implicated in the mechanism of gastroprotection but their 
role in the healing process of chronic gastric ulcers has been little investigated. Previous 
studies by [Sibilia et al., 2003] and our group [Brzozowski et al., 2004; Brzozowski et al., 2006 
b.; Konturek et al., 2004] revealed that that central and peripheral administration of ghrelin 
reduced the formation of acute gastric lesions induced by ethanol and cold stress. It was 
proposed that NO and sensory neuropeptides mediate these gastroprotective effects of 
ghrelin because the blockade of NO-synthase (NOS) activity with L-NAME and the 
functional ablation of sensory afferent nerves with capsaicin attenuated the protection and 
gastric hyperemia induced by ghrelin [Brzozowski et al., 2004; Brzozowski et al., 2006a.; 
Dimitrova et al., 2010]. In contrast to prevention of acute damage to the mucosal structure, 
the healing of chronic gastric ulcers lasts days and weeks and may involve restoration of 
gland architecture, angiogenesis and scar formation and it remains unknown whether 
appetite hormones may influence these processes.  
Recently, endogenous prostaglandins (PG) have been implicated in the control of food 
intake and appetite [Lugarini et al., 2002; Scholz, 2003] but the possibility that these 
arachidonate metabolites may play any important role in the mechanism of ghrelin or 
orexin-A affecting ulcer healing has not been explored. This prompted our interest in 
endogenous PG because these arachidonate metabolites play an essential role in the 
mechanism of gastric defense and ulcer healing [Brzozowski et al., 2001] but the importance 
of PG derived from cyclooxygenase (COX-1) and COX-2  in the possible ulcer healing effects 
of orexigenic peptides has not been so far determined.   
This study was designed to compare the effects of daily intraperitoneal (i.p.) administration 
of vehicle, ghrelin, orexin-A and obestatin on healing of preexisting gastric ulcers and 
accompanying changes in the gastric blood flow (GBF) at ulcer margin and the generation of 
PGE2 in the gastric mucosa. An attempt was made to examine the effect of antagonism of 
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GHS-R1a and OX-A1 receptors with D-lys3GHRP-6 and SB334867 [Peeters, 2005; Smart et 
al., 2001] respectively, on spontaneous ulcer healing and the alteration in ulcer size induced 
by ghrelin and orexin-A. We also determined the effects of PG inhibition with  a non-
selective (indomethacin) and selective cyclooxygenase (COX)-1 (SC-560) and COX-2 
(rofecoxib) inhibitors and blockade with L-NNA, the NO-synthase inhibitor on healing of 
these ulcers and accompanying changes in the GBF in rats without and with ghrelin or 
orexin-A administration. In addition, the expression of ghrelin mRNA at the ulcer margin 
and that in non-ulcerated gastric mucosa was assessed in rats with gastric ulcer. Finally, 
ghrelin rats were concomitantly treated with obestatin to check whether obestatin, recently 
considered as physiological opponent of ghrelin regarding food intake and appetite control 
[Zhang et al., 2005], could influence the ulcer healing itself and affect the healing and 
hyperemic effects of ghrelin.   
2. Material and methods  
Male Wistar rats, weighing 200-250 g and fasted for 24 h were used in all studies. All 
experimental procedures were run according to Helsinki Declaration and approved by the 
Jagiellonian University Institutional Animal Care and Use Committee. 
2.1 Production of gastric ulcers  
Gastric ulcers were produced in rats using our modification (19) of acetic acid method 
originally proposed by Okabe et al. (1971) with our group modification [Konturek et al., 
1987]. Animals were anesthetized with ether, the stomach was exposed and 75 l of acetic 
acid was poured through the plastic mold (6 mm diameter) onto serosal surface of anterior 
wall of the stomach just proximal to the antral gland area for 25 s. This produced an 
immediate necrosis of the entire mucosa and submucosa (but not serosa) within the area 
where the acetic acid was applied, i.e., about 28 mm2. The excess of acetic acid was then 
removed and the serosa was gently washed out with saline. Our previous studies 
documented that these ulcers became chronic within 2-3 days and healed completely within 
2-3 weeks without perforation or penetration to the surrounding organs as described in 
original technique [Konturek et al., 1987; Okabe et al., 1971]. After the application of acetic 
acid the animals were allowed to recover from anesthesia and received only water at the day 
of operation (day 0). Then, they were divided into various groups and received normal 
chow and water ad libitum for the next 9 days and then were sacrificed.  
2.2 Effect of orexin-A, ghrelin without and with the antagonists of ghrelin and orexin-A 
receptors on ulcer healing and the alterations in GBF at ulcer margin  
Several groups of rats with gastric ulcers, each consisting of 6-8 animals, were treated daily 
either with 1) vehicle (saline), 2) ghrelin or orexin-A (2.5-30 g/kg-d i.p.), 3) D-Lys3-GHRP-6 
(200 g/kg i.p.), the ghrelin receptor antagonist (Peeters, 2005), or SB 334867 which is a 
selective non-peptide OX-R1 receptor antagonist [Smart, et al., 2001; Holland, et al., 2006] 
administered alone or in the combination with ghrelin and orexin-A (standard dose of 30 
g/kg-d i.p.), respectively. SB 334867 was dissolved in DMSO and kept in a 20 mM solution 
as recommended by manufacturer [Tocris Cookson Ltd., Bristol, UK]. The dose of OX-R1 
antagonist used in this study was selected on the basis of our earlier studies (unpublished 
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observation) with dose-dependent inhibition of orexin-A protection against WRS damage 
obtained with this orexin-A antagonist.  
In another group of animals with gastric ulcers and treated with COX-1 and COX-2 
inhibitors with or without ghrelin, orexin-A and obestatin administration, the effect of 
prostaglandin replacement therapy using 16,16 dimethyl PGE2 [Upjohn, Kalamazoo, MI, 
USA] applied i.g. in a dose of 5 g/kg-d was examined. This dose of dimethyl PGE2 was 
found in our preliminary study to be without any influence on ulcer healing and 
accompanying fall in GBF at ulcer margin. For this reason, synthetic PGE2 analog was 
administered together with each COX-1 or COX-2 inhibitor with or without ghrelin, orexin-
A and obestatin administration.  
Upon the termination of experiment, the animals were anesthetized with pentobarbital, their 
abdomen was opened by midline incision and the stomach exposed for measurement of 
GBF by means of the H-gas clearance technique as described previously [Brzozowski et al., 
2000 a]. For this purpose two electrodes of an electrolytic regional blood flow meter 
(Biotechnical Science, Model RBF-2, Osaka, Japan) were inserted into the gastric mucosa. 
The measurements were made in three areas of the oxyntic mucosa at ulcer margin and the 
mean values were calculated and expressed as percent changes of those recorded in the 
control animals. After GBF measurement, the stomach was removed, rinsed with saline and 
pinned open for macroscopic examination. The area of gastric lesions was determined by 
computerized planimetry (Morphomat, Carl Zeiss, FRG) [Brzozowski et al., 2000 b] by a 
researcher blind to the experimental grouping.    
Samples of the oxyntic gland area from the ulcer margin were taken by biopsy (about 100 
mg) immediately after the animals were sacrificed to determine the mucosal generation of 
PGE2 by specific radioimmunoassay (RIA) as described previously [Konturek et al., 1995; 
Brzozowski et al., 2000]. PGE2 was measured in duplicate using RIA kits (New England 
Nuclear, Munich, Germany). The mucosal generation of PGE2 was expressed in nanograms 
per gram of wet tissue weight.    
2.3 Effect of ghrelin and orexin-A on the healing of acetic acid ulcers and 
accompanying changes in the GBF at ulcer margin. Involvement of the COX-PG and 
NO-NOS systems in ghrelin-induced acceleration of ulcer healing  
The involvement of the COX-PG system in the ulcer healing effects of ghrelin was studied in 
rats treated with (or without) indomethacin, a non-selective COX-1 and COX-2 inhibitor, 
and with SC-560, a selective COX-1 inhibitor or rofecoxib, a specific COX-2 inhibitor 
[Brzozowski et.al., 1999]. In the experimental protocol, the following groups of rats, each 
consisting of 6-8 animals, were used: 1) vehicle (saline 1 ml i.p.); 2) ghrelin, orexin-A  or 
obestatin, each applied in a standard dose of 30 g/kg-d i.p.; 2) indomethacin (5 mg/kg 
i.p.), SC-560 (5 mg/kg-d i.g.) and rofecoxib (10 mg/kg-d i.g.), each applied alone or co-
administered with ghrelin, orexin-A or obestatin (30 g/kg-d i.p.). The doses of SC-560 and 
rofecoxib were selected on the basis of previous studies showing that these agents almost 
completely suppress PGE2 generation in exudates of air-pouch inflammation and inhibit 
gastric PGE2 production in mucosa with preexisting gastric ulcer [Futaki et al., 1993; Lesch et 
al., 1998]. SC-560 (Cayman Chemical Co., Ann Arbor, Michigan, USA) was first dissolved in 
absolute ethanol to obtain a stock solution of 50 mg/ml and then diluted to the desired 
concentration with isotonic saline. Rofecoxib [Sharp & Dhome, Warsaw, Poland] was first 
dissolved in methanol to obtain a stock solution 75 mg/ml and then diluted to the desired 
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concentration with isotonic saline. Control rats received the corresponding vehicle. Our 
preliminary studies (data not included) showed that none of the COX inhibitors used in this 
study produced by itself any gastric lesions at the doses tested. At the dose used in the 
present study, indomethacin has been shown previously to inhibit gastric PGE2 generation 
by ~ 90 % without itself causing any mucosal damage [Konturek et al., 1987]. 
In another group of animals with gastric ulcers and treated with COX-1 and COX-2 
inhibitors with or without ghrelin, orexin-A and obestatin administration, the effect of 
prostaglandin replacement therapy using 16, 16 dimethyl PGE2 (Upjohn, Kalamazoo, MI, 
USA) applied i.g. in a dose of 5 g/kg-d was examined. This dose of dimethyl PGE2 was 
found in our preliminary study to be without any influence on ulcer healing and 
accompanying fall in GBF at ulcer margin. For this reason, synthetic PGE2 analog was 
administered together with each COX-1 or COX-2 inhibitor with or without ghrelin, orexin-
A and obestatin administration.  
Upon the termination of experiment, the animals were anesthetized with pentobarbital, their 
abdomen was opened by midline incision and the stomach exposed for measurement of 
GBF by means of the H-gas clearance technique as described previously [Brzozowski et al., 
2000 a]. For this purpose two electrodes of an electrolytic regional blood flow meter 
(Biotechnical Science, Model RBF-2, Osaka, Japan) were inserted into the gastric mucosa. 
The measurements were made in three areas of the oxyntic mucosa at ulcer margin and the 
mean values were calculated and expressed as percent changes of those recorded in the 
control animals. After GBF measurement, the stomach was removed, rinsed with saline and 
pinned open for macroscopic examination. The area of gastric lesions was determined by 
computerized planimetry (Morphomat, Carl Zeiss, FRG) [Brzozowski et al., 2000b] by a 
researcher blind to the experimental grouping.    
Samples of the oxyntic gland area from the ulcer margin were taken by biopsy (about 100 
mg) immediately after the animals were sacrificed to determine the mucosal generation of 
PGE2 by specific radioimmunoassay (RIA) as described previously [Konturek et al., 1995]. 
PGE2 was measured in duplicate using RIA kits (New England Nuclear, Munich, Germany). 
The mucosal generation of PGE2 was expressed in nanograms per gram of wet tissue 
weight.    
2.4 Determination of plasma ghrelin, orexin-A and obestatin levels by 
radioimmunoassay 
At the termination of some experiments with obestatin applied i.p. alone or co- 
administered with ghrelin, the rats were anesthetized with pentobarbital and blood samples 
(about 3 ml) taken from the vena cava  for the measurement of plasma ghrelin, orexin-A and 
obestatin levels by RIA. Intact rats fasted overnight and given only vehicle (saline) i.p. were 
measured similarly in order to determine control values for plasma ghrelin, orexin-A and 
obestatin concentration. Blood samples were collected in heparin coated polypropylene 
tubes and centrifuged at 3000 rpm for 20 minutes at 4oC. The supernatant was then stored at 
-80C until measurement of plasma ghrelin, orexin-A and obestatin levels using an RIA-kit 
for rat ghrelin, orexin-A and obestatin  (Phoenix Peptide, Belmont, CA, USA) [Brzozowski et 
al., 2004; Brzozowski et. al., 2006 b]. Briefly, the ghrelin, orexin-A and obestatin RIA 
involved the competition of each rat peptide sample with 125I-rat ghrelin, orexin-A and 
obestatin tracers for binding to a specific rabbit anti-ghrelin-, anti-orexin-A- and anti-
obestatin polyclonal antibody. The limit of assay sensitivity for ghrelin, orexin-A and 
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obestatin were 3 pg, 6pg  and 5 pg per tube, the intra-assay variation was less than 8%,7% 
and 9%, and the interassay variation less than 5%, 4% and 7%, respectively.  
2.5 Reverse-transcriptase-polymerase chain reaction (RT-PCR) for detection of 
messenger RNA (mRNA) for ghrelin and proinflammatory cytokines IL-1 and TNF- 
in rats without and with gastric ulcers 
The stomachs were removed from vehicle (control) rats for the determination of ghrelin 
mRNA expression using specific primers by RT-PCR. Gastric mucosal specimens were 
scraped off from oxyntic mucosa using a slide glass and immediately snap frozen in liquid 
nitrogen and stored at -80C until analysis. Total RNA was extracted from mucosal samples 
by a guanidium isothiocyanate/phenol chloroform method using a kit from Stratagene 
(Heidelberg, Germany). Single stranded cDNA was generated from 5 g of total cellular 
RNA using StrataScript reverse transcriptase and oligo-(dT)-primers (Stratagene, 
Heidelberg, Germany). The polymerase chain reaction mixture was amplified in a DNA 
thermal cycler (Perkin-Elmer-Cetus, Norwalk, CT) in an area set aside for performing the 
PCR reaction. The nucleotide sequences of the primers for ghrelin and -actin were selected 
on the basis of the published cDNA encoding ghrelin and -actin, respectively [Konturek et 
al., 2004; Brzozowski et al., 2006 b]. The sense primer for ghrelin was 5-
TTGAGCCCAGAGCACCAGAAA-3, and the antisense primer was 5-
AGTTGCAGAGGAGGCAGAAGCT-3. The IL-1β primer sequences were designed 
according to the published cDNA sequence for primer sequences and were as follows: up-
stream, 5' GCT ACC TAT GTC TTG CCC GT; downstream, 3' GAC CAT TGC TGT TTC 
CTA GG. The expected length product was 543 bp. The TNF- primer sequences were as 
follows: up-stream, 5'TAC TGA ACT TCG GGG TGA TTG GTC C; downstream, 3' CAG 
CCT TGT CCC TTG AAG AGA ACC. The expected length product was 295 bp [Konturek et 
al., 2010]. The oligonucleotide sequences for -actin were TTG TAA CCA ACT GGG ACG 
ATA TGG (sense) and GAT CTT GAT CTT CAT GGT GCT AGG (antisense). The primers 
were synthesized by GIBCO BRL/Life Technologies, Eggenstein, Germany. The signals for 
ghrelin mRNA was standardized against the -actin signal for each sample and results were 
expressed as the ratio of ghrelin mRNA to -actin mRNA.   
3. Results 
3.1 Effect of treatment with orexin-A, ghrelin and obestatin on ulcer healing and the 
accompanying changes in the GBF at ulcer margin 
The effect of i.p. administration of orexin-A applied in graded doses ranging from 1 
g/kg-d up to 30 g/kg-d and ghrelin administered in a dose of 30 g/kg-d (i.p.) on acetic 
acid-induced gastric ulcers are shown in Fig.1. Orexin-A dose-dependently reduced the 
ulcer area, the dose inhibiting this area by 50% (ED50) was 15 g/kg.  
Almost double reduction of the ulcer area was obtained with orexin-A administered at the 
dose 30 g/kg as compared with control rats injected i.p. with vehicle (saline). This 
reduction in ulcer area achieved with orexin-A  was accompanied by the dose-dependent 
increase in GBF. Ghrelin administered in a dose of 30 g/kg-d i.p. significantly reduced the 
ulcer area and significantly increased GBF with the extent similar to that observed with 
orexin-A applied in the highest dose. Eight days of i.p. administration of obestatin applied 
in graded doses ranging from 2.5 g/kg up to 30 g/kg-d, dose-dependently reduced the 
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Fig. 1. The area of gastric ulcer induced by acetic acid and gastric blood flow (GBF) at ulcer 
margin at 8 day upon ulcer induction in rats treated with vehicle (saline) or with various 
doses of orexin-A (1 - 30 g/kg-d i.p.) or ghrelin (30 g/kg-d i.p.). Means  SEM of 6-8 rats. 
Asterisk indicates a significant change (p<0.05) as compared to the vehicle-control values.  
area of gastric ulcer and significantly increased the GBF at ulcer margin starting from the 
dose of 5 g/kg (Fig. 2). The maximal reduction of ulcer area accompanied by a significant 
rise in the GBF at ulcer margin was recorded at the dose of 30 g/kg of obestatin where 35% 
reduction of ulcer area and an increase by about 19% of GBF at ulcer margin were observed 
as compared to the respective values in vehicle-treated animals.  
3.2 Role of cyclooxygenase (COX)-1 and COX-2 inhibition and the blockade of nitric 
oxide (NO)  synthase on ulcer healing activity and alterations in the GBF at ulcer 
margin in rats treated with ghrelin, orexin-A and obestatin 
As shown in Fig. 3, ghrelin and orexin-A given i.p. in dose 30 g/kg-d significantly 
decreased ulcer area and enhanced GBF as compared to those observed in vehicle. 
Treatment with D-Lys3-GHRS-6 (200 g/kg i.p.), the ghrelin GHS-R1a  receptor  antagonist, 
by itself failed to affect the area of gastric ulcers and GBF at ulcer margin at day 8 upon ulcer 
induction.  The decrease in the area of these ulcers and accompanying rise in the GBF at 
ulcer margin induced by ghrelin and orexin-A were significantly attenuated by concurrent 
treatment with ghrelin and orexin-A receptor antagonists, D-Lys3-GHRS-6 and SB334867. 
The administration of D-lys3GHRP, which is a specific ghrelin receptor antagonist or 
SB334867, an antagonist of orexin-A OXR-1 receptors when applied alone, failed to affect the 
area of gastric ulcer and the GBF at ulcer margin as compared to those measured in vehicle-
treated rats. Treatment with D-lys3GHRP significantly attenuated ghrelin-induced 
acceleration of ulcer healing and the accompanying increase in GBF at ulcer margin. 
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Concomitant treatment of orexin-A with its receptor antagonist, SB334867 (5 mg/kg-d s.c.), 
completely abolished the reduction in ulcer area induced by orexin-A. This antagonist of 
orexin-A receptors reversed also an increase in GBF at ulcer margin caused by orexin-A. 
 
 
Fig. 2. The area of gastric ulcers and the alterations in the GBF at ulcer margin in rats treated 
for 8 days with vehicle (Veh; control) or obestatin applied i.p. in graded doses ranging from 
2.5  g/kg-d up to 30 g/kg-d. Mean  SEM of 6-8 rats. Asterisk indicates a significant 
change (p<0.05) compared to the vehicle-pretreated controls. 
As shown in Fig. 4, treatment with ghrelin, orexin-A and obestatin (30 g/kg-d i.p.) resulted in 
a similar attenuation in the area of gastric ulcer and a similar rise in GBF as that shown in Figs. 
1 and 2. The mucosal generation of PGE2 was significantly increased at ulcer margin as 
compared to the respective value in the non-ulcerated control (1289 vs. 18912 ng/g wet 
tissue weight, p<0.05). Ghrelin, orexin-A and obestatin applied i.p. resulted in a significant 
increase in the PGE2 generation at ulcer margin as compared to vehicle-treated animals with 
gastric ulcer (18912 vs 23419 ng/g, 18912 vs 2289 ng/g and 18912 vs 2198 ng/g, 
respectively, p<0.05). Indomethacin (5 mg/kg i.p.), which by itself significantly increased the 
ulcer area, suppressed the generation of PGE2 by about 85% (p<0.02) and produced a 
significant fall in GBF as compared to vehicle-pretreated animals (Fig. 4). Treatment with this 
non-selective COX-1 and COX-2 inhibitor completely abolished the reduction in the area of 
gastric ulcers and the accompanying rise in GBF evoked by ghrelin, orexin-A and obestatin. 
The decrease in the area of ulcer and accompanying increase in GBF caused by ghrelin, orexin-
A and obestatin as well as the rise in the PGE2 generation they induced were also significantly 
attenuated by pretreatment with rofecoxib, the selective COX-2 inhibitor (Fig. 4). SC-560 (5 
mg/kg-d i.g.), which by itself significantly reduced the PGE2 generation (not shown), 
significantly attenuated the ghrelin-, orexin-A- and obestatin-induced decrease in ulcer area 
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and the accompanying rise in GBF at ulcer margin (Fig. 4). Concurrent treatment with a 
minute amount of synthetic dimethyl analog of PGE2 (5 g/kg-d i.g.) in addition to ghrelin, 
orexin-A and obestatin restored the decrease in the ulcer area and the increase in GBF at ulcer 
margin in rats treated with indomethacin, SC-560 or rofecoxib (Fig. 4).  
 
 
Fig. 3. The area of gastric ulcers and the accompanying changes in the GBF at ulcer margin 
in rats with or without ghrelin or orexin-A (both at a dose of 30 g/kg-d i.p.) applied 
without or with the ghrelin receptor antagonist D-Lys3-GHSR-6 (200 g/kg-d i.p.) or orexin-
A receptor antagonist SB334867 (200 g/kg-d i.p.). Mean  SEM of 6-8 rats. Asterisk 
indicates a significant change (p<0.05) compared to the vehicle-pretreated controls. Cross 
indicates a significant change (p<0.05) compared to the values obtained in rats treated with 
ghrelin and orexin-A without the concurrent treatment with GHS-R1a receptor or OXR-1 
receptor antagonists.  
3.3 Expression of ghrelin and proinflammatory cytokines in ulcer area during ulcer 
healing without and with ghrelin treatment  
The effect of eight day administration of L-NNA (20 mg/kg-d i.p.), the NO-synthase 
inhibitor on ulcer area  and the changes in GBF at ulcer margin in rats treated without and 
with vehicle, ghrelin, orexin-A and obestatin, each applied in a dose of  30 g/kg-d i.p. is 
presented in Fig. 5. Treatment with ghrelin, orexin-A and obestatin significantly reduced the 
ulcer area and increased the GBF at ulcer margin as shown in Fig. 4. Treatment with L-
NNA, which by itself significantly enhanced ulcer area also significantly decreased GBF at 
ulcer margin as compared to respective values in vehicle-control. Concurrent treatment with 
L-NNA together with ghrelin, orexin-A and obestatin reversed the ghrelin-, orexin-A- and 
obestatin-induced decrease in ulcer area and the accompanying rise in the GBF at ulcer 
margin.  
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Fig. 6 shows that ghrelin was expressed in intact non-ulcerated gastric mucosa and that with 
gastric ulcer. Ghrelin mRNA expression was detected as the strong signal in intact gastric 
mucosa and vehicle-treated gastric mucosa with gastric ulcer. Ratio of mRNA for ghrelin 
over -actin revealed that this ratio was significantly higher in ulcerated gastric mucosa as 
in case of that in intact animals without an ulcer (Fig. 6, left panel).  
 
 
Fig. 4. The area of gastric ulcers and the accompanying changes in the GBF at ulcer margin  
in rats treated for a period of 8 days with vehicle (saline) and ghrelin, orexin-A and 
obestatin (each given in a dose of 30 g/kg-d i.p.) with or without the concurrent treatment 
with indomethacin (5 mg/kg-d i.p.), rofecoxib (10 mg/kg-d i.g.) or SC-560 (5 mg/kg-d i.g.) 
applied alone or combined with synthetic 16,16 dimethyl (dm) PGE2 analog (5 g/kg-d i.g.). 
Mean  SEM of 6-8 rats. Asterisk indicates a significant decrease (p<0.05) as compared to the 
value obtained in vehicle-controls. Asterisk and cross indicate a significant increase (p<0.05) 
as compared to vehicle-treated controls administered without or with ghrelin, orexin-A or 
obestatin. Cross indicate a significant change (p<0.02) as compared to respective values 
obtained in animals treated with indomethacin, SC-560 or rofecoxib without the concurrent 
treatment with PGE2 analog.  
As shown in Fig. 7, the signal of mRNA for IL-1 and TNF- mRNAs was faintly expressed 
in intact gastric mucosa but it was observed as strong signal in vehicle-control mucosa of 
animals with gastric ulcer. Ratio of mRNA for ghrelin over -actin indicated that expression 
of mRNA for IL-1 and TNF- was significantly increased in vehicle-treated rats with 
gastric ulcer over that recorded in intact gastric mucosa. In contrast, in rats treated with 
ghrelin applied i.p. at the doses of 15 g/kg and 30 g/kg, the signal for IL-1 and TNF- 
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mRNAs was significantly decreased in gastric mucosa with gastric ulcer as compared to that 
in vehicle-control animals. Ratio of mRNA for IL-1 and TNF- mRNA over -actin mRNA 
revealed that this ratio was significantly decreased in gastric mucosa of rats treated with 
ghrelin administered at the dose of 15 g/kg. The ratio of IL-1 and TNF- was significantly 
decreased in animals treated with ghrelin applied i.p in a higher dose of 30 g/kg than in 
those treated with ghrelin administered in a lower dose of 15 g/kg of this peptide (Fig. 7).  
 
 
 
Fig. 5. The area of gastric ulcers and the accompanying changes in the GBF at ulcer margin 
in rats treated with vehicle (Veh; saline-control), ghrelin, orexin-A and obestatin (each 
administered in a dose of 30 g/kg-d i.p.) applied without or with the NO-synthase 
inhibitor L-NNA (20 mg/kg-d i.p.). Mean  SEM of 6-8 rats. Asterisk indicates a significant 
change (p<0.05) compared to the vehicle-treated controls. Asterisk and cross indicate a 
significant change (p<0.05) compared to the values obtained in rats treated with vehicle. 
Cross indicates the significant change (p<0.02) compared to the values obtained in ghrelin, 
orexin-A and obestatin without the concurrent treatment with L-NNA.  
3.4 Effect of treatment with obestatin on ulcer healing in rats with of ghrelin 
administration 
Fig. 8 shows the effects of eight day of concomitant administration of ghrelin, the appetite 
stimulating peptide, and obestatin which is opponent of ghrelin acting as the natural ligand 
of the GPR39 receptor, on the alterations in area of gastric ulcer and accompanying changes 
in GBF at ulcer area and plasma ghrelin and obestatin levels. Ghrelin and obestatin given 
i.p. in the same comparable dose of 30 g/kg-d significantly reduced the area of gastric 
ulcer, however the significantly greater reduction in ulcer area was observed in ghrelin- 
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Fig. 6. Determination of expression of -actin and ghrelin mRNAs (left panel) by RT-PCR 
and the ratio of ghrelin to -actin mRNA (right panel) in non-ulcerated (intact) gastric 
mucosa (lane Intact) and in gastric mucosa at ulcer margin (lane Ulcer), M - DNA size 
marker. Mean  SEM of 4-6 rats. Asterisk indicates a significant change (p<0.05) as 
compared to the value obtained in non-ulcerated gastric mucosa.  
treated rats as compared with those treated with obestatin. Plasma ghrelin level increased 
after i.p. administration of exogenous ghrelin but remained unchanged after combined 
treatment of ghrelin with obestatin as compared with those treated with ghrelin alone. The 
plasma obestatin concentration which was significantly increased in obestatin-treated rats 
with gastric ulcer was not significantly affected by the concurrent ghrelin administration as 
compared to vehicle-treated rats. The combined treatment of obestatin co-administered with 
ghrelin failed to significantly the affect the ghrelin-induced attenuation of ulcer area and the 
accompanying rise in plasma ghrelin level which reached similar values, as in case of 
ghrelin administered alone.  
4. Discussion 
This study shows that appetite hormones such as ghrelin, orexin-A and obestatin besides 
their well recognized action in the control of food intake and energy expenditure, exhibit 
ulcer healing and hyperemic activities as documented by an acceleration of ulcer healing by 
these peptides accompanied by an increase in the GBF at ulcer margin. These healing and 
hyperemic effects of ghrelin and orexin A seem to be very specific because both hormones 
induced acceleration of the healing and hyperemia at ulcer margin were reversed by ghrelin 
receptor antagonist D-Lys3-GHRP-6, and orexin-A receptor antagonist SB 334867, 
respectively, indicating that ghrelin- and orexin A-induced ulcer healing promoting and 
hyperemic effects are mediated by the functionally active form of GHS-R1a receptor and 
orexin (OX-R1) receptors. These receptors GHS-R1a and OX-R1 have been shown to bind 
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Fig. 7. Determination of expression of -actin, IL-1 and TNF- mRNAs (left panel) by RT-
PCR and the ratio of mRNA for ghrelin, orexin-A and obestatin (each administered at the 
dose of 30 g/kg-d i.p.) to -actin mRNA (right panel) in intact non-ulcerated gastric 
mucosa and in those with acetic acid-induced gastric ulcer treated with vehicle (saline) or 
ghrelin applied i.p. in a dose of 15 g/kg or 30 g/kg, M - DNA size marker. Mean  SEM 
of 4-6 rats. Asterisk indicates a significant change (p<0.05) as compared to the value 
obtained in intact non-ulcerated gastric mucosa. Asterisk and cross indicate a significant 
change (p<0.05) as compared to the value obtained in animals treated eight days with 
ghrelin administered daily i.p. at the dose of 15 g/kg-d.  
acylated ghrelin and orexin A, respectively. Moreover, we found that ghrelin, orexin A and 
to lesser extent also obestatin increased the PGE2 generation at ulcer margin and that these 
peptides ulcer healing promoting and hyperemic effects and an increase in PGE2 generated 
at ulcer margin were significantly attenuated by non-selective (indomethacin), selective 
COX-1 (SC-560) and selective COX-2 inhibitors (rofecoxib). These findings indicate that 
endogenous PG derived from both COX-1 and COX-2 enzymatic pathways are involved in 
the mechanism of ulcer healing by these hormones. Obestatin which was originally claimed 
to act as ghrelin opponent in the regulation of appetite behaviour [Zhang et. al., 2005], also 
accelerated ulcer healing and increased the GBF at ulcer margin in our study though these 
effects were less pronounced as compared with those of ghrelin and orexin-A.  
Ghrelin is a recently described 28-amino acid peptide that has been discovered in rat and 
human gastrointestinal tract, particularly in gastric mucosa, as an endogenous ligand for 
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Fig. 8. The area of gastric ulcers and the alterations in the GBF at ulcer margin in rats treated 
for 8 days with vehicle (Veh, saline) or ghrelin (30 g/kg-d i.p.) without or with concurrent 
treatment with obestatin (30 g/kg-d i.p.).  Mean  SEM of 6-8 rats. Asterisk indicates a 
significant change (p<0.05) compared to vehicle-control- or obestatin-treated rats. Asterisk 
and cross indicate a significant change (p<0.05) compared to rats treated with ghrelin.   
growth hormone secretagogue receptor (GHS-R) [Kojima et al., 1999, Hosoda et. al., 2000]. 
Previous studies revealed that two GHS-R subtypes are generated by alternative splicing of a 
single gene: the full-length type 1a receptor (GHS-R1a) and a carboxyl-terminally truncated 
GHS-R type 1b (GHS-R1b) [Peeters , 2005; Brzozowski et al., 1999]. The GHS-R1a is the 
functionally active, signal transducing form of the GHS-R, while the GHS-R1b is devoid of 
high-affinity ligand binding and signal transduction activity. Ghrelin molecules, produced by 
endocrine cells of gastric glands exist in two major molecular forms, ghrelin and 
des-n-octanoyl ghrelin (des-acyl ghrelin) [Hosoda et al., 2000; Fukuhara et al., 2005]. The 
acylation by n-octanoic acid of the hydroxyl group of their third residue, which is either serine 
or threonine, is essential for binding of ghrelin to the GHS-R1a [Hosoda et al., 2000]. We 
attempted in this study to determine whether the expected ulcer healing activity of ghrelin and 
orexin A is due to a direct activation of GHS-1a and orexin A receptors or involves other 
mediators or receptors, as yet uncharacterized and distinct from the GHS-R and orexin A. We 
have found that the acceleration of healing and the functional features of this healing such as 
an improvement in the GBF at ulcer area, the crucial mechanism involved in the healing of 
gastric ulcer, were mediated by specific ghrelin and orexin-A receptors.  
Ghrelin was originally reported to exhibit gastroprotective activity against mucosal lesions 
induced by corrosive substances such as ethanol as well as against damage induced by 
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stress and ischemia-reperfusion [Sibilia et al., 2003; Brzozowski et al., 2004; Konturek et al., 
2004; Brzozowski et al., 2006]. These effects were associated with a significant increase in 
plasma ghrelin concentration as well as marked attenuation of the fall in GBF provoked by 
stress and I/R but remained independent on gastric acid secretory activity of this peptide 
[Brzozowski et al., 2006]. This study attempted to determine the effects of graded doses of 
exogenous orexin-A and obestatin compared with ghrelin on healing of acetic acid ulcers 
and GBF at ulcer margin and PGE2 generation in the gastric mucosa. We found that 
peripherally administered orexin-A dose-dependently accelerated ulcer healing, elevated 
mucosal generation of PGE2 and raised GBF at ulcer margin. Ghrelin and obestatin also 
accelerated ulcer healing with the magnitude similar to orexin-A while causing an increase 
in GBF and PGE2 generation in the ulcerated gastric mucosa. The key finding of this study is 
the demonstration that ghrelin mRNA is upregulated in the margin of gastric ulcer 
suggesting that endogenous ghrelin might reduce the size of the ulcer and improve the 
microcirculation around the ulcer bed. Interestingly, ghrelin mRNA was also increased in 
the gastric mucosa exposed to ischemia-reperfusion suggesting that enhanced expression of 
transcripts of ghrelin may limit the extent of gastric damage provoked by I/R. Thus, our 
study is in partial agreement with previous observations that plasma ghrelin is increased 
following stress-induced gastric lesions, and that its enhanced immunoreactivity is 
associated with duodenal ulcerations induced by cysteamine in rats [Brzozowski et al., 2006; 
Fukuhara et al., 2005].  
Since endogenous prostaglandins (PGs) have been implicated in the control of food intake 
and appetite [Eberhart, E.C, 1995; Scholz, H, 2003] we hypothesized that these 
cytoprotective arachidonate metabolites could play an important role in the healing effect of 
ghrelin. This prompted our interest in endogenous PGs because their role as well as the 
importance of expression of cyclooxygenase (COX-1) and COX-2 at ulcer margin in the 
possible ulcer activity of appetite hormones such as ghrelin, orexin-A and obestatin have not 
been studied. The present study supports the notion that the ulcer healing and hyperemic 
activities of ghrelin, orexin-A and obestatin during the time-course of ulcer healing involve 
an increase in mucosal generation of endogenous PGs. Previous studies have established 
that PG synthesis depends upon the activity of cyclooxygenase (COX), a rate limiting 
enzyme in the synthesis of eicosanoids from arachidonic acid [Eberhart CE & Dubois RN, 
1995]. In contrast to COX-1, COX-2 is not constitutively expressed in most of tissues, but is 
dramatically upregulated during inflammation and ulcer healing [Takeuchi et al., 2004; 
Brzozowski et al., 2006] and following inhibition of mucosal COX-1 activity [Davies et al., 
1997; Tanaka et al., 2002; Takeuchi et al., 2004]. First, we found that all hormones tested that 
is mean ghrelin, orexin A and obestatin  enhance the PGE2 generation at ulcer margin as 
compared with that of vehicle-control at day 8 upon ulcer induction. Second, indomethacin 
almost completely abolished, while SC-560, the selective COX-1 inhibitor and rofecoxib, the 
selective COX-2 inhibitor, greatly attenuated the ulcer healing and hyperemic effects of 
ghrelin, orexin A and obestatin, indicating that endogenous PGs, potentially derived from 
the activities of both COX-1 and COX-2, are responsible for the putative beneficial effects of 
this peptide on ulcer healing. It is of interest that COX-1 and COX-2 inhibitors by themselves 
delayed ulcer healing and abolished the ulcer healing promoting activity of ghrelin, orexin 
A and obestatin and counteracted their accompanying rise in GBF at ulcer margin 
suggesting that endogenous PG might be considered as primary mediators involved in the 
mechanism of ulcer healing by these peptides.  
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It is not excluded that the beneficial effect of these hormones depend also upon the 
activation of NO/NOS system by these hormones, which is an important metabolic 
pathway involved in the mechanism of mucosal defense and ulcer healing. The involvement 
of cNOS/iNOS-NO system in ulcer healing and the possible role of ghrelin in ulcer healing 
are not quite clear from this and other studies [Sibillia et al., 2009]. Although the non-
specific suppression of cNOS/iNOS-NO system by L-NNA was found in our study to delay 
ulcer healing, little is known whether appetite hormones could affect the expression and 
activity of cNOS or iNOS or both. Indeed, the concurrent treatment with L-NNA not only 
markedly reduced the acceleration of ulcer healing but also the accompanying hyperemia at 
ulcer margin caused by these hormones. This finding suggests that NO could be considered 
as one of the essential mediator of both, the ulcer healing and the hyperemic activity of 
ghrelin, orexin A and obestatin. Thus we propose that NO possibly derived from 
constitutive cNOS rather than inducible iNOS expression and activity, plays an important 
role in the ghrelin-, orexin A and obestatin induced acceleration of the ulcer healing process. 
However, factors other than  endogenous PGs and NO, possibly also sensory neuropeptides 
such as CGRP could also contribute to this effect, and therefore, their involvement in ulcer 
healing activity of ghrelin, orexin A and obestatin should be addressed in future studies. 
The finding that COX-1 and COX-2 inhibitors greatly attenuated  the ulcer healing activity 
of ghrelin, is in keeping with the observation that ghrelin is ineffective in the protection 
against indomethacin-induced gastric ulcers [Sibillia et al., 2004], where the mucosal 
generation of PGE2 is greatly suppressed. 
Interestingly, the overexpression of TNF-a and IL-1 was detected in vehicle treated 
control rats with gastric ulcer comparing to intact gastric mucosa , and this effect was 
probably caused by severe tissue ischemia, resulting from the application of acetic acid. This 
overexpression of proinflammatory cytokines such as TNF- and IL-1, likely contributed to 
early tissue damage and formation of ulceration. As reported by our group recently 
[Brzozowski et al., 2006] vascular injury leading to ischemia is the major factor associated 
with early induction of acute mucosal damage and also involved in the time-course of 
chronic ulceration in the stomach, where the acetic acid was applied. [Guo et al., 2003] 
reported an early rise in the expression of iNOS, suggesting that this expression 
accompanied by excessive generation of NO possibly forming peroxynitrate, was probably 
responsible for the enlargement of ulcer crater observed at early first days upon ulcer 
induction by acetic acid in rats. Our results seem to support this notion by overexpression of 
mRNA for proinflammatory cytokines, TNF- and IL-1, that could be responsible for the 
formation of focal tissue damage caused by acetic acid application. Treatment with ghrelin 
markedly attenuated the expression of IL-1 and TNF- in gastric mucosa around the ulcer 
suggesting that the acceleration of ulcer healing by ghrelin could be, at least in part, due to 
the potent anti-inflammatory activity of this hormone.   
We reported before that the induction of gastric ulcer by serosal application of acetic acid is 
accompanied by the co-expression of gastroprotective COX-2-PG system with the increased 
expression and release of vasoactive, proliferative and trophic gastric hormones such as 
gastrin and ghrelin [Konturek et al., 2008]. Ghrelin was shown to exhibit gastroprotective 
activity and our present study confirming that this hormone can accelerate ulcer healing, 
suggests that the upregulation in the ghrelin gene expression could play the central event in 
the mechanism of gastric ulcer healing. These protective and trophic hormonal responses of 
gastric mucosa to ulceration, as manifested by increased expression of ghrelin co-expressed 
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with COX-2 [Konturek et al., 2008]  possibly triggered by an overexpression of  IL-1 and 
TNF-, seem to play a crucial role in the restoration cellular and glandular structure of the 
mucosa and the quality of ulcer healing.  
Interestingly, obestatin, which is encoded by the same gene as ghrelin has recently been 
reported to counteract physiological effects of ghrelin [Zhang et al., 2005]. Intraperitoneal 
and intracerebroventricular treatment with obestatin suppressed food intake in a time-
dependent and dose-dependent manner. This was supported by observation that obestatin 
effectively blunted the hunger caused by short-term starvation and inhibited feeding or 
body weight in rats [Sibillia et al., 2009] and food consumption in mice [Lagaut et al., 2007]. 
However, the vast majority of studies indicates that obestatin exerts little or no effects on 
food intake and body weight and failed to modify the CCK-induced decrease in food intake 
[Moechrs et al., 2006; Nogueiras et al., 2007; Tremblay et al., 2007]. Our present findings are 
in keeping with these latter observations because obestatin by itself accelerated ulcer healing 
but when administered together with ghrelin, remained without influence on ghrelin 
induced promotion of the ulcer healing and an increase in the GBF at ulcer margin and 
plasma ghrelin levels. This suggests that obestatin might not be considered as physiological 
opponent of ghrelin with the respect to ulcer healing activity which clearly was enhanced by 
this peptide.  
5. Conclusion 
In summary, these results demonstrate for the first time, that administration of exogenous 
ghrelin dose-dependently accelerates healing of chronic gastric ulcers and that other 
hormones involved in the control of appetite and food intake such as orexin-A and obestatin 
can also exert beneficial effect on the speed of ulcer healing. An evidence was provided that 
these ulcer healing effects of orexin-A, ghrelin and obestatin may depend upon endogenous 
PGs derived from COX-1 and COX-2 activity and an enhancement of gastric 
microcirculation around the ulcer area, possibly mediated by NO. Our finding that ghrelin 
is expressed in gastric mucosa, particularly at ulcer margin during ulcer healing suggests 
that this hormone may act locally by paracrine pathway to activate the vasoactive 
compounds such as PG and NO that may lead to an acceleration of the ulcer healing and the 
suppression of the mucosal expression and the release of proinflammatory cytokines TNF- 
and IL-1.  
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